P2Y2 receptor polymorphisms and haplotypes in cystic fibrosis and their impact on Ca2+ influx

Pharmacogenetics and Genomics

Volumn 16, Issue 3, 2006, Pages 199-205

  Büscher, Rainer ^a   Hoerning, André ^a   Patel, Hemal H ^b   Zhang, Shen ^b   Arthur, David B ^b   Grasemann, Hartmut ^c   Ratjen, Felix ^c   Insel, Paul A ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Calcium signalling; CFTR; Cl secretion; FEV1; P2Y2 receptor gene; Polymorphisms; Pulmonary function

Indexed keywords

ARGININE; CALCIUM ION; CYSTEINE; LEUCINE; MESSENGER RNA; PROLINE; PURINE P2Y2 RECEPTOR; SERINE; CALCIUM; PURINE P2 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CHILD; CODON; CONTROLLED STUDY; CYSTIC FIBROSIS; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; GENETIC POLYMORPHISM; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PHARMACOGENETICS;

ADOLESCENT; ADULT; CALCIUM; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, PURINERGIC P2; VARIATION (GENETICS);

EID: 33644596353     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Gonzalez FA, Weisman GA, Erb L, Seye CI, Sun GY, Velazquez B, et al. Mechanisms for inhibition of P2 receptors signalling in neural cells. Mol Neurobiol 2005; 31:65-79.
2. Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 2004; 240:301-304.
3. Shaver SR. P2Y receptors: biological advances and therapeutic opportunities. Curr Opin Drug Discov Devel 2001; 4:665-670.
4. Weisman GA, Wang M, Kong Q, Chorna NE, Neary JT, Sun Gy, et al. Molecular determinants of P2Y2 nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes. Mol Neurobiol 2005; 31:169-184.
5. Rost S, Daniel C, Schulze-Lohoff E, Baumert HG, Lambrecht G, Hugo C. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangial proliferative glomerulonephritis. Kidney Int 2002; 62:1659-1671.
6. Nichols KK, Yerxa B, Kellerman DJ. Diquafosol tetrasodium: a novel dry eye therapy. Expert Opin Investig Drugs 2004; 13:47-54.
7. Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004; 23:784-792.
8. Thorne PR, Munoz DJ, Nikolic P, Mander L, Jagger DJ, Greenwood D, et al. Potential role of purinergic signalling in cochlear pathology. Audiol Neurootol 2002; 7:180-184.
9. Kellerman D, Evans R, Mathews D, Shaffer C. Inhaled P2Y2 receptor agonists as a treatment for patients with cystic fibrosis lung disease. Adv Drug Deliv Rev 2002; 54:1463-1474.
10. Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005; 39:339-348.
11. Kellerman DJ. P2Y2 receptor agonists: a new class of medication targeted at improved mucociliary clearance. Chest 2002; 121:201S-205S.
12. Pidlaoan LV, Jin J, Sandhu AK, Athwal RS, Kunapuli SP. Colocalization of P2Y2 and P2Y6 receptor genes at human chromosome 11q13.3-14.1. Somat Cell Mol Genet 1997; 23:291-296.
13. Parr CE, Sullivan DM, Paradiso AM, Lazarowski ER, Burch LH, Olsen JC, et al. Cloning and expression of a human P2U nucleotide receptor a target for cystic fibrosis pharmacotherapy. Proc Natl Acad Sci USA 1994; 91:3275-3279.
14. Janssens R, Paindavoine P, Parmentier M, Boeynaems JM. Human P2Y2 receptor polymorphism: identification and pharmacological characterization of two allelic variants. Br J Pharmacol 1999; 127:709-716.
15. Grasemann H, van's Gravesande KS, Büscher R, Drazen JM, Ratjen F. Effects of sex and of gene variants in constitutive nitric oxide synthases on exhaled nitric oxide. Am J Respir Crit Care Med 2003; 167:1113-1116.
16. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6(Suppl 16):5-40.
17. Zhang S, Remillard CV, Fantozzi I, Yuan JX. ATP-induced mitogenesis is mediated by cyclic AMP response element-binding protein-enhanced TRPC4 expression and activity in human pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol 2004; 287:1192-1201.
18. WHO/ICF. Therapeutic approaches for cystic fibrosis: memorandum from a joint WHO/ICF (M) A meeting. Bull World Health Organ 1994; 72:341-352.
19. Büscher R, Eilmes KJ, Grasemann H, Torres B, Knauer N, Sroka K, et al. β2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmcogenetics 2002; 12:347-353.
20. Grasemann H, Knauer N, Büscher R, Hübner K, Drazen JM, Ratjen F. Airway nitric oxide levels in cystic fibrosis patients are regulated to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med 2000; 162:2172-2176.
21. Saadane A, Soltys J, Berger M. Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. J Allergy Clin Immunol 2005; 115:405-411.
22. VirellaLowell I, Herlihy JD, Liu B, Lopez C, Cruz P, Muller C, et al. Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell line. Mol Ther 2004; 10:562-573.
23. + T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin Exp Immunol 1996; 106:374-388.
24. Davies J, Alton E, Griesenbach U. Cystic fibrosis modifier genes. J R Soc Med 2005; 98(Suppl 45):47-54.
25. Mekus F, Laabs U, Veeze H, Tümmler B. Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs. Hum Genet 2003; 112:1-11.
26. Guggino WB, Banks-Schlegel SP. Macromolecular interactions and ion transport in cystic fibrosis. Am J Respir Crit Care Med 2004; 170:815-820.
27. Kunzelmann K, Mall M. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Am J Respir Med 2003; 2:299-309.
28. Roomans GM. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis. Am J Respir Med 2003; 2:413-431.
29. Kanoh S, Kondo M, Tamaoki J, Kobayashi H, Motoyoshi K, Nagai A. Differential regulations between adenosine triphosphate (ATP)- and uridine triphosphate-induced Cl (-) secretion in bovine and tracheal epithelium. Am J Respir Cell Mol Biol 2001; 25:370-376.
30. Kumari R, Goh G, Ng LL, Boarder MR. ATP and UTP responses of cultured rat aortic smooth muscle cells revisited: dominance of P2Y2 receptors. Br J Pharmacol 2003; 140:1169-1176.
31. Burnstock G. Introduction: P2 receptors. Curr Top Med Chem 2004; 4:793-803.
32. Hoehe MR, Timmermann B, Lehrach H. Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr Pharm Biotechnol 2003; 4:351-378.
33. Kirstein SL, Insel PA. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev 2004; 56:31-52.